AI Article Synopsis

  • The study focused on the prevalence and management of severe asthma using nationwide data from Sweden, Norway, and Finland, highlighting limited real-life evidence on the condition.
  • Researchers utilized the Nordic Dataset for Asthma Research (NORDSTAR) to identify severe asthma cases in adults and children, finding prevalence rates across the countries in 2018.
  • Results revealed that while severe asthma was relatively rare in children, a significant number of patients, especially adults, were not managed by respiratory specialists, indicating a need for better awareness and management in primary care settings.

Article Abstract

Background: Real-life evidence on prevalence and management of severe asthma is limited. Nationwide population registries across the Nordic countries provide unique opportunities to describe prevalence and management patterns of severe asthma at population level. In nationwide register data from Sweden, Norway and Finland, we examined the prevalence of severe asthma and the proportion of severe asthma patients being managed in specialist care.

Methods: This is a cross-sectional study based on the Nordic Dataset for Asthma Research (NORDSTAR) research collaboration platform. We identified patients with severe asthma in adults (aged ≥18 years) and in children (aged 6-17 years) in 2018 according to the European Respiratory Society/American Thoracic Society definition. Patients managed in specialist care were those with an asthma-related specialist outpatient contact (only available in Sweden and Finland).

Results: Overall, we identified 598 242 patients with current asthma in Sweden, Norway and Finland in 2018. Among those, the prevalence of severe asthma was 3.5%, 5.4% and 5.2% in adults and 0.4%, 1.0%, and 0.3% in children in Sweden, Norway and Finland, respectively. In Sweden and Finland, 37% and 40% of adult patients with severe asthma and two or more exacerbations, respectively, were managed in specialist care; in children the numbers were 56% and 41%, respectively.

Conclusion: In three Nordic countries, population-based nationwide data demonstrated similar prevalence of severe asthma. In children, severe asthma was a rare condition. Notably, a large proportion of patients with severe asthma were not managed by a respiratory specialist, suggesting the need for increased recognition of severe asthma in primary care.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068510PMC
http://dx.doi.org/10.1183/23120541.00687-2022DOI Listing

Publication Analysis

Top Keywords

severe asthma
48
asthma
14
prevalence management
12
severe
12
nordic countries
12
sweden norway
12
norway finland
12
prevalence severe
12
managed specialist
12
patients severe
12

Similar Publications

Recent studies have highlighted the critical role of lipid metabolism in macrophages concerning lung inflammation. However, it remains unclear whether lipid metabolism is involved in macrophage extracellular traps (METs). We analyzed the GSE40885 dataset from the GEO database using weighted correlation network analysis (WGCNA) and further selection using the least absolute shrinkage and selection operator (LASSO) regression.

View Article and Find Full Text PDF

What's in a Clade? Clinical Impact of Rhinovirus Serotype on the Development and Severity of Asthma Exacerbations.

J Allergy Clin Immunol Pract

January 2025

Division of Asthma, Allergy and Immunology, Department of Medicine, Carter Immunology Center, University of Virginia Health Systems, Charlottesville, Va. Electronic address:

View Article and Find Full Text PDF

Background: Biologics can induce remission in some patients with severe asthma, however, little is known about pre-biologic disease trajectories and their association with outcomes from biological treatment. We aimed to identify long-term trajectories of disease progression in patients initiating biologics and investigate trajectory associations with disease burden and impact on biologic therapy efficacy.

Methods: Patients in the Danish Severe Asthma Registry initiating biologic therapy between 2016-2022 were included and followed retrospectively in prescription databases starting 1995.

View Article and Find Full Text PDF

Objective: In severe equine asthma, structural remodeling of the airways ultimately leads to bronchial wall thickening and airflow obstruction. Increased bronchial vascularization has been described in horses affected by the severe form of the disease, but whether it contributes to bronchial remodeling in milder forms of asthma remains to be determined. In a blinded, retrospective case-control study, we evaluated the presence of bronchial angiogenesis in horses with mild and moderate equine asthma (MEA) and its correlation to airway smooth muscle remodeling.

View Article and Find Full Text PDF

Montelukast, a leukotriene receptor antagonist (LTRA) approved for the treatment of asthma and allergic rhinitis, is widely used, though real-world data on its application in asthma management remain limited. This registry-based study evaluated the use of montelukast in adult asthma patients, examining demographic and disease characteristics, asthma control status, asthma phenotypes, presence of atopy, and treatment regimens. Among 2053 patients analyzed, 61.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!